HomeGeneticsConditionZellweger spectrum disorder
Back to Condition
Zellweger spectrum disorder
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Zellweger spectrum disorder

Zellweger spectrum disorder is a condition that affects many parts of the body, caused by the impaired formation of peroxisomes.

Overview

Zellweger spectrum disorder is a condition that affects many parts of the body. Cases of Zellweger spectrum disorder are often categorized as severe, intermediate, or mild.

Individuals with severe Zellweger spectrum disorder usually have signs and symptoms at birth, which worsen over time. These infants experience weak muscle tone (hypotonia), feeding problems, hearing and vision loss, and seizures. These problems are caused by reduced myelin, which is the covering that protects nerves and promotes the efficient transmission of nerve impulses. The part of the brain and spinal cord that contains myelin is called white matter. Reduced myelin (demyelination) leads to loss of white matter (leukodystrophy).

Children with severe Zellweger spectrum disorder also develop life-threatening problems in other organs and tissues, such as the liver, heart, and kidneys, and their liver or spleen may be enlarged. They may have skeletal abnormalities, including a large space between the bones of the skull (fontanelles) and characteristic bone spots known as chondrodysplasia punctata that can be seen on x-ray. Affected individuals can have eye abnormalities, including clouding of the lenses of the eyes (cataracts) or involuntary, side-to-side movements of the eyes (nystagmus). Severe Zellweger spectrum disorder involves distinctive facial features, including a flattened face, epicanthal folds, high forehead, and widely spaced eyes (hypertelorism). Children with severe Zellweger spectrum disorder typically do not survive beyond the first year of life.

People with intermediate or mild Zellweger spectrum disorder have more variable features that progress more slowly than those with the severe form. Affected children usually do not develop signs and symptoms of the disease until late infancy or early childhood. Children with these intermediate and mild forms often have hypotonia, vision problems, hearing loss, liver dysfunction, developmental delay, and some degree of intellectual disability.

Frequency

Zellweger spectrum disorder is estimated to occur in 1 in 50,000 individuals.

Causes

Variants in at least 12 genes have been found to cause Zellweger spectrum disorder. These genes provide instructions for making a group of proteins known as peroxins, which are essential for the formation and normal functioning of cell structures called peroxisomes. Peroxisomes are sac-like compartments that contain enzymes needed to break down many different substances, including fatty acids and certain toxic compounds. They are also important for the production of fats (lipids) used in digestion and in the nervous system.

Variants in the genes that cause Zellweger spectrum disorder prevent peroxisomes from forming normally. Diseases that disrupt the formation of peroxisomes, including Zellweger spectrum disorder, are called peroxisome biogenesis disorders. If the production of peroxisomes is altered, these structures cannot perform their usual functions. The signs and symptoms of severe Zellweger spectrum disorder are due to the absence of functional peroxisomes within cells. Intermediate and mild Zellweger spectrum disorder are caused by variants that allow some peroxisomes to form.

Variants in the PEX1 gene are the most common cause of Zellweger spectrum disorder and are found in nearly 70 percent of affected individuals.

Gene associated with Zellweger spectrum disorder

  • PEX1

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have variants. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

  • Cerebrohepatorenal syndrome
  • PBD, ZSS
  • PBD-ZSD
  • Peroxisome biogenesis disorders, Zellweger syndrome spectrum
  • Zellweger spectrum
  • Zellweger syndrome spectrum
  • ZSD

Frequently Asked Questions

While no cure exists, certain dietary modifications can reduce metabolic burden. A low‑fat, medium‑chain triglyceride (MCT) diet may help limit very‑long‑chain fatty acid accumulation. Omega‑3 fatty acid supplementation and vitamin E can support neuronal health, but all interventions should be supervised by a metabolic dietitian to avoid deficiencies.
Families should coordinate multidisciplinary care, including neurologists, hepatologists, ophthalmologists, and developmental therapists. Regular monitoring of liver function, vision, hearing, and growth is essential. Early intervention services for motor and speech delays, along with safe feeding practices (e.g., thickened feeds or feeding tubes if needed), can improve quality of life. Regular follow‑up for cardiac and renal evaluations is also recommended.
Newborns with Zellweger spectrum disorder often present with poor muscle tone (hypotonia), feeding difficulties, seizures, and abnormal eye movements such as nystagmus. If a baby shows a combination of these symptoms—especially if they are persistent or worsening—prompt referral to a metabolic or genetics specialist is advised. Early evaluation can help initiate supportive care and plan for potential complications.
Diagnosis typically starts with a biochemical screen for elevated very‑long‑chain fatty acids, bile acid intermediates, and plasmalogens in blood or urine. If abnormal, a molecular genetic test—usually next‑generation sequencing of the PEX genes—is performed to identify pathogenic variants. A confirmed genetic diagnosis guides prognosis and family counseling.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA